Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Erratum for Schooley et al., "Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection".

Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e02221-18. doi: 10.1128/AAC.02221-18. Print 2018 Dec. No abstract available.

2.

Virtual Screening, Biological Evaluation, and 3D-QSAR Studies of New HIV-1 Entry Inhibitors That Function via the CD4 Primary Receptor.

Zhang C, Zhang H, Huang LS, Zhu S, Xu Y, Zhang XQ, Schooley RT, Yang X, Huang Z, An J.

Molecules. 2018 Nov 20;23(11). pii: E3036. doi: 10.3390/molecules23113036.

3.

Maternally Acquired Zika Antibodies Enhance Dengue Disease Severity in Mice.

Fowler AM, Tang WW, Young MP, Mamidi A, Viramontes KM, McCauley MD, Carlin AF, Schooley RT, Swanstrom J, Baric RS, Govero J, Diamond MS, Shresta S.

Cell Host Microbe. 2018 Nov 14;24(5):743-750.e5. doi: 10.1016/j.chom.2018.09.015.

PMID:
30439343
4.

The Evolution of Mentorship Capacity Development in Low- and Middle-Income Countries: Case Studies from Peru, Kenya, India, and Mozambique.

Noormahomed E, Williams P, Lescano AG, Raj T, Bukusi EA, Schooley RT, Cohen CR.

Am J Trop Med Hyg. 2018 Nov 14. doi: 10.4269/ajtmh.18-0560. [Epub ahead of print]

PMID:
30430979
5.
6.

Monitoring of Delay to Pharmacy Refill in Assessing Adherence to Antiretroviral Therapy.

Cruz CCP, Mistro S, Mendes CMC, Schooley RT, da Silva Badaró RJ.

J Pharm Pract. 2018 Aug 20:897190018795339. doi: 10.1177/0897190018795339. [Epub ahead of print]

PMID:
30122111
7.

The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies.

Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ.

J Infect Dis. 2018 Nov 5;218(12):1954-1963. doi: 10.1093/infdis/jiy479.

PMID:
30085241
8.

Phage Therapy for a Multidrug-Resistant Acinetobacter baumannii Craniectomy Site Infection.

LaVergne S, Hamilton T, Biswas B, Kumaraswamy M, Schooley RT, Wooten D.

Open Forum Infect Dis. 2018 Mar 23;5(4):ofy064. doi: 10.1093/ofid/ofy064. eCollection 2018 Apr.

9.

Expression of concern relating to Naucler et al.

Schooley RT.

Clin Infect Dis. 2018 Apr 13. doi: 10.1093/cid/ciy316. [Epub ahead of print] No abstract available.

PMID:
29669001
10.

Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection.

Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL, Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L, McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA, Young R, Hamilton T.

Antimicrob Agents Chemother. 2017 Sep 22;61(10). pii: e00954-17. doi: 10.1128/AAC.00954-17. Print 2017 Oct. Erratum in: Antimicrob Agents Chemother. 2018 Nov 26;62(12):.

11.

The Medical Education Partnership Initiative (MEPI), a collaborative paradigm for institutional and human resources capacity building between high- and low- and middle-income countries: the Mozambique experience.

Virgínia Noormahomed E, Carrilho C, Ismail M, Noormahomed S, Nguenha A, Benson CA, Mocumbi AO, Schooley RT.

Glob Health Action. 2017;10(1):1272879. doi: 10.1080/16549716.2017.1272879.

12.

A Conversation Among the IAS-USA Board of Directors: Hot Topics and Emerging Data in HIV Research and Care.

Benson CA, Currier JS, Del Rio C, Gallant JE, Gulick RM, Marrazzo JM, Richman DD, Saag MS, Schooley RT, Volberding PA.

Top Antivir Med. 2017 Dec/Jan;24(4):142-151.

13.

Skating to Where the Puck Is Going to Be.

Schooley RT, Fang FC.

Clin Infect Dis. 2017 Jan 1;64(1):1-2. No abstract available.

PMID:
27986765
14.

Rapid Multiplexed Immunoassay for Detection of Antibodies to Kaposi's Sarcoma-Associated Herpesvirus.

Logan C, Todorof K, Fiorillo SP, Campbell TB, Elder JH, Borok M, Gudza I, Gwanzura L, Ndemera B, Lochhead MJ, Benson CA, Schooley RT.

PLoS One. 2016 Sep 26;11(9):e0163616. doi: 10.1371/journal.pone.0163616. eCollection 2016.

15.

Our Warming Planet: Is the HIV-1-Infected Population in the Crosshairs.

Schooley RT.

Top Antivir Med. 2016 Jul/Aug;26(2):67-70.

16.

Nasal commensal Staphylococcus epidermidis counteracts influenza virus.

Chen HW, Liu PF, Liu YT, Kuo S, Zhang XQ, Schooley RT, Rohde H, Gallo RL, Huang CM.

Sci Rep. 2016 Jun 16;6:27870. doi: 10.1038/srep27870.

17.

Vitamin D Metabolites Inhibit Hepatitis C Virus and Modulate Cellular Gene Expression.

Gutierrez JA, Jones KA, Flores R, Singhania A, Woelk CH, Schooley RT, Wyles DL.

J Virol Antivir Res. 2014 Oct 6;3(3). doi: 10.4172/2324-8955.1000129.

18.

A prospective observational study of bacteraemia in adults admitted to an urban Mozambican hospital.

Preziosi M, Zimba TF, Lee K, Tomas M, Kinlin S, Nhatave-Paiva C, Bene R, Paunde T, Lopes H, Kalkhoff S, Prathap V, Akrami K, Noormahomed EV, Schooley RT, Aronoff-Spencer E.

S Afr Med J. 2015 Apr 8;105(5):370-4. doi: 10.7196/samj.8780.

19.

Reply to Christopher and Kortepeter.

Schooley RT.

Clin Infect Dis. 2015 Nov 1;61(9):1489-90. doi: 10.1093/cid/civ567. Epub 2015 Jul 14. No abstract available.

PMID:
26175523
20.

Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection.

Carlin AF, Aristizabal P, Song Q, Wang H, Paulson MS, Stamm LM, Schooley RT, Wyles DL.

Hepatology. 2015 Oct;62(4):1047-58. doi: 10.1002/hep.27971. Epub 2015 Aug 22.

21.

Presence of Plasmodium falciparum DNA in Plasma Does Not Predict Clinical Malaria in an HIV-1 Infected Population.

Orlov M, Smeaton LM, Kumwenda J, Hosseinipour MC, Campbell TB, Schooley RT.

PLoS One. 2015 Jun 8;10(6):e0129519. doi: 10.1371/journal.pone.0129519. eCollection 2015.

22.

Near patient CD4 count in a hospitalized HIV patient population.

Givens M, Weaver A, Bickman S, Logan C, Noormahomed EV, Patel S, Schooley RT, Benson CA, Lochhead MJ.

Cytometry B Clin Cytom. 2017 Nov;92(6):451-455. doi: 10.1002/cyto.b.21248. Epub 2015 May 27.

23.

Editorial Commentary: All's (Almost) Quiet on the Western Front: Will We Be Ready for the Next War?

Schooley RT.

Clin Infect Dis. 2015 Aug 15;61(4):503-5. doi: 10.1093/cid/civ337. Epub 2015 Apr 22. No abstract available.

PMID:
25904373
24.

Determination of receptor specificities for whole influenza viruses using multivalent glycan arrays.

Huang ML, Cohen M, Fisher CJ, Schooley RT, Gagneux P, Godula K.

Chem Commun (Camb). 2015 Mar 28;51(25):5326-9. doi: 10.1039/c4cc08613a.

25.

Relationship of HIV reservoir characteristics with immune status and viral rebound kinetics in an HIV therapeutic vaccine study.

Li JZ, Heisey A, Ahmed H, Wang H, Zheng L, Carrington M, Wrin T, Schooley RT, Lederman MM, Kuritzkes DR; ACTG A5197 Study Team.

AIDS. 2014 Nov 28;28(18):2649-57. doi: 10.1097/QAD.0000000000000478.

26.

Innovative strategies for transforming internal medicine residency training in resource-limited settings: the Mozambique experience.

Mocumbi AO, Carrilho C, Aronoff-Spencer E, Funzamo C, Patel S, Preziosi M, Lederer P, Tilghman W, Benson CA, Badaró R, Nguenha A, Schooley RT, Noormahomed EV.

Acad Med. 2014 Aug;89(8 Suppl):S78-82. doi: 10.1097/ACM.0000000000000331.

27.

Interferon γ-induced protein 10 kinetics in treatment-naive versus treatment-experienced patients receiving interferon-free therapy for hepatitis C virus infection: implications for the innate immune response.

Lin JC, Habersetzer F, Rodriguez-Torres M, Afdhal N, Lawitz EJ, Paulson MS, Zhu Y, Subramanian GM, McHutchison JG, Sulkowski M, Wyles DL, Schooley RT.

J Infect Dis. 2014 Dec 15;210(12):1881-5. doi: 10.1093/infdis/jiu325. Epub 2014 Jun 6.

28.

Antigen-presenting phagocytic cells ingest malaria parasites and increase HIV replication in a tumor necrosis factor α-dependent manner.

Orlov M, Vaida F, Williamson K, Deng Q, Smith DM, Duffy PE, Schooley RT.

J Infect Dis. 2014 Nov 15;210(10):1562-72. doi: 10.1093/infdis/jiu317. Epub 2014 Jun 5.

29.

Relationship of vitamin D insufficiency to AIDS-associated Kaposi's sarcoma outcomes: retrospective analysis of a prospective clinical trial in Zimbabwe.

Erlandson KM, Gudza I, Fiorillo S, Ndemera B, Schooley RT, Gwanzura L, Borok M, Campbell TB.

Int J Infect Dis. 2014 Jul;24:6-10. doi: 10.1016/j.ijid.2014.02.006. Epub 2014 Apr 21.

30.

The fragile relationship between hepatitis C virus and its human host.

Schooley RT.

Top Antivir Med. 2014 Jan;21(5):148-51. Review.

31.

Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.

Boltz VF, Bao Y, Lockman S, Halvas EK, Kearney MF, McIntyre JA, Schooley RT, Hughes MD, Coffin JM, Mellors JW; OCTANE/A5208 Team.

J Infect Dis. 2014 Mar 1;209(5):703-10. doi: 10.1093/infdis/jit635. Epub 2014 Jan 16.

32.

Strengthening research capacity through the medical education partnership initiative: the Mozambique experience.

Noormahomed EV, Mocumbi AO, Preziosi M, Damasceno A, Bickler S, Smith DM, Funzamo C, Aronoff-Spencer E, Badaró R, Mabila F, Bila D, Nguenha A, Do Rosário V, Benson CA, Schooley RT, Patel S, Ferrão LJ, Carrilho C.

Hum Resour Health. 2013 Dec 5;11:62. doi: 10.1186/1478-4491-11-62.

33.

Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase.

Cohen M, Zhang XQ, Senaati HP, Chen HW, Varki NM, Schooley RT, Gagneux P.

Virol J. 2013 Nov 22;10:321. doi: 10.1186/1743-422X-10-321.

34.

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices.

Afdhal NH, Zeuzem S, Schooley RT, Thomas DL, Ward JW, Litwin AH, Razavi H, Castera L, Poynard T, Muir A, Mehta SH, Dee L, Graham C, Church DR, Talal AH, Sulkowski MS, Jacobson IM; New Paradigm of HCV Therapy Meeting Participants.

J Viral Hepat. 2013 Nov;20(11):745-60. doi: 10.1111/jvh.12173. Review.

35.

Decreased memory T-cell response and function in human immunodeficiency virus-infected patients with tegumentary leishmaniasis.

Gois LL, Mehta S, Rodrigues MZ, Schooley RT, Badaró R, Grassi MF.

Mem Inst Oswaldo Cruz. 2014 Feb;109(1):9-14. doi: 10.1590/0074-0276130174. Epub 2013 Oct 2.

36.

Reply to Messori et al.

Mistro S, Schooley RT, Badaro R.

Clin Infect Dis. 2013 Dec;57(12):1784-5. doi: 10.1093/cid/cit591. Epub 2013 Oct 17. No abstract available.

PMID:
24140973
37.

Inhibitory and combinatorial effect of diphyllin, a v-ATPase blocker, on influenza viruses.

Chen HW, Cheng JX, Liu MT, King K, Peng JY, Zhang XQ, Wang CH, Shresta S, Schooley RT, Liu YT.

Antiviral Res. 2013 Sep;99(3):371-82. doi: 10.1016/j.antiviral.2013.06.014. Epub 2013 Jun 29.

38.

Performance evaluation of the MBio Diagnostics point-of-care CD4 counter.

Logan C, Givens M, Ives JT, Delaney M, Lochhead MJ, Schooley RT, Benson CA.

J Immunol Methods. 2013 Jan 31;387(1-2):107-13. doi: 10.1016/j.jim.2012.10.002. Epub 2012 Oct 11.

39.

Darunavir is a good third-line antiretroviral agent for HIV type 1-infected patients failing second-line protease inhibitor-based regimens in South India.

Saravanan S, Madhavan V, Balakrishnan P, Smith DM, Solomon SS, Sivamalar S, Poongulali S, Kumarasamy N, Schooley RT, Solomon S, Kantor R.

AIDS Res Hum Retroviruses. 2013 Mar;29(3):630-2. doi: 10.1089/AID.2011.0334. Epub 2012 Dec 7.

40.

Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.

Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, Grinsztejn B, Hosseinipour MC, Kumwenda J, Lalloo U, Riviere C, Sanchez J, Melo M, Supparatpinyo K, Tripathy S, Martinez AI, Nair A, Walawander A, Moran L, Chen Y, Snowden W, Rooney JF, Uy J, Schooley RT, De Gruttola V, Hakim JG; PEARLS study team of the ACTG.

PLoS Med. 2012;9(8):e1001290. Epub 2012 Aug 14.

41.

A cross-sectional study of sub-clinical Plasmodium falciparum infection in HIV-1 infected and uninfected populations in Mozambique, South-Eastern Africa.

Noormahomed EV, Orlov M, do Rosario V, Petersen BW, Guthrie C, Badaro R, Schooley RT.

Malar J. 2012 Aug 1;11:252. doi: 10.1186/1475-2875-11-252.

42.

P. falciparum enhances HIV replication in an experimental malaria challenge system.

Orlov M, Vaida F, Finney OC, Smith DM, Talley AK, Wang R, Kappe SH, Deng Q, Schooley RT, Duffy PE.

PLoS One. 2012;7(6):e39000. doi: 10.1371/journal.pone.0039000. Epub 2012 Jun 26.

43.

Hepatitis C virus therapeutics: at the end of the beginning.

Schooley RT.

Top Antivir Med. 2012 Apr-May;20(1):17-9. No abstract available.

44.

Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis.

Mistro S, Maciel Ide M, de Menezes RG, Maia ZP, Schooley RT, Badaró R.

Clin Infect Dis. 2012 Jun;54(12):1774-7. doi: 10.1093/cid/cis290. Epub 2012 Apr 5. Review.

PMID:
22491505
45.

Characteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trial.

Li JZ, Brumme CJ, Lederman MM, Brumme ZL, Wang H, Spritzler J, Carrington M, Medvik K, Walker BD, Schooley RT, Kuritzkes DR; AIDS Clinical Trials Group A5197 Study Team.

PLoS One. 2012;7(3):e34134. doi: 10.1371/journal.pone.0034134. Epub 2012 Mar 30.

46.

Unusual insertion and deletion at codon 67 and 69 of HIV type 1 subtype C reverse transcriptase among first-line highly active antiretroviral treatment-failing South Indian patients: association with other resistance mutations.

Saravanan S, Madhavan V, Kantor R, Sivamalar S, Gomathi S, Solomon SS, Kumarasamy N, Smith DM, Schooley RT, Solomon S, Balakrishnan P.

AIDS Res Hum Retroviruses. 2012 Dec;28(12):1763-5. doi: 10.1089/AID.2011.0331. Epub 2012 May 21.

47.

Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.

Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, Luz PM, Freedberg KA, Wood R, Levison JH, Mugyenyi PN, Salata R, Wallis CL, Weinstein MC, Schooley RT, Walensky RP.

AIDS. 2012 Jun 1;26(9):1083-93. doi: 10.1097/QAD.0b013e32835221eb.

48.

Interferon-alpha administration enhances CD8+ T cell activation in HIV infection.

Manion M, Rodriguez B, Medvik K, Hardy G, Harding CV, Schooley RT, Pollard R, Asmuth D, Murphy R, Barker E, Brady KE, Landay A, Funderburg N, Sieg SF, Lederman MM.

PLoS One. 2012;7(1):e30306. doi: 10.1371/journal.pone.0030306. Epub 2012 Jan 24.

49.

Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals.

Zhu H, Wong-Staal F, Lee H, Syder A, McKelvy J, Schooley RT, Wyles DL.

J Infect Dis. 2012 Feb 15;205(4):656-62. doi: 10.1093/infdis/jir802.

50.

Rapid multiplexed immunoassay for simultaneous serodiagnosis of HIV-1 and coinfections.

Lochhead MJ, Todorof K, Delaney M, Ives JT, Greef C, Moll K, Rowley K, Vogel K, Myatt C, Zhang XQ, Logan C, Benson C, Reed S, Schooley RT.

J Clin Microbiol. 2011 Oct;49(10):3584-90. doi: 10.1128/JCM.00970-11. Epub 2011 Aug 24.

Supplemental Content

Loading ...
Support Center